Last updated on October 2018

A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma


Brief description of study

The purpose of this study is to evaluate the safety/tolerability and efficacy of itacitinib in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Clinical Study Identifier: NCT02760485

Contact Investigators or Research Sites near you

Start Over

Incyte Corporation Call Center

Mount Sinai Comprehensive Cancer Center
Miami Beach, FL United States
4.22miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.